Cancer pts: 2013 to 2017, the national opioid prescribing rate declined by 20.7% among oncologists and 22.8% among non-oncologists

Opioid Prescribing for Cancer Care Drops

https://www.drugtopics.com/view/opioid-prescribing-for-cancer-care-drops

The rate of prescribing opioids among both oncologists and non-oncologists has dropped significantly in the past few years, raising concerns for patient care, according to a recent study.

In the wake of the US opioid epidemic, there have been major efforts to curb opioid prescribing. Researchers at Yale University School of Medicine set out to discover whether the efforts have affected prescribing among oncologists, whose patients often require opioids for symptom management.

Their findings, recently published in the Journal of the National Cancer Institute, showed that, from 2013 to 2017, the national opioid prescribing rate declined by 20.7% among oncologists and 22.8% among non-oncologists.1

During the 5-year period, 43 states reported a decrease in opioid prescribing among oncologists. In 5 states, opioid prescribing decreased more among oncologists than non-oncologists, according to the study.

From 2013 to 2017, prescribing of gabapentin increased by 5.9% among oncologists and 23.1% among oncologists and non-oncologists, respectively. Among palliative care providers, opioid prescribing increased by 15.3%.

“Given similar declines in opioid prescribing among oncologists and non-oncologists, there is concern that opioid prescribing guidelines intended for the non-cancer population are being applied inappropriately to patients with cancer and survivors,” wrote Vikram Jairam, MD, with the department of therapeutic radiology at Yale University School of Medicine.

It is reasonable to assume that the steep drop in opioid prescribing rates among oncologists is related to the “seismic shifts in prescribing regulations and attitudes toward opioids,” wrote Andrea C. Enzinger, MD, and Alexi A. Wright, MD, MPH, both with the Dana-Farber Cancer Institute in Boston, Massachusetts , in a companion editorial.

“The period studied overlaps with the rapid expansion of state opioid legislation establishing prescription drug monitoring programs (PDMPs), mandating provider education, and requiring patient identification and pharmacist verification prior to opioid dispensing,” they wrote. “Prescription drug plans also began imposing limits on the quantity, dose, or duration of opioid prescriptions, further reducing prescribing.”

Writing an opioid prescription has become a complex process that involves signing controlled substance agreements, checking PDMPs, filling prior authorization paperwork, communicating with pharmacists, and “even rewriting prescriptions to comply with seemingly arbitrary and sometimes conflicting rules set by states, insurers, and pharmacies,” Enzinger and Wright wrote.

“These burdens likely disincentivized oncologists from prescribing, potentially shifting this responsibility to palliative care — as evidenced by the 15% increase in opioid prescribing observed among palliative care physicians,” they wrote. “To protect cancer patients’ access, it is critical for policy solutions to lessen — rather than add to — oncology providers’ workload.”

4 Responses

  1. I had to watch my mother die in unimaginable bone pain from leukemia; they refused to even consider anything except Children’s Liquid Tylenol –even after she was completely unable to swallow anything. There was not the slightest doubt that she was dying; it was her 7th relapse & they knew attempting chemo would kill her faster than the leukemia (she might’ve been better off, even given how horrendous the chemo was; at least it would’ve been shorter than the month of utter Hell she had to go thru).

    I’ve never really recovered, mentally or emotionally, from the experience…& this was in ’97, back when they were talking about treating pain being a good thing, at least for the dying. I can’t even begin to imagine the scale of the suffering from the barbaric torture that is being committed nowadays to cancer & non-cancer patients alike…I only know how much I’m suffering. I hope there is a Hell, & all those greedy, sadistic —–s responsible for this hysterical insanity go there….after suffering years of unendurable agony before they die.

    • PS:
      “‘To protect cancer patients’ access, it is critical for policy solutions to lessen — rather than add to — oncology providers’ workload.”’

      I’d say it’s critical to RESTORE access for non-cancer patients as well*…the divide between cancer pain & non-cancer pain is as unreasonably insane as the rest of this moronic, cataclysmically hypocritical country’s opioid policies.

      *to say “protect” is beyond absurd; a better term would be “restore” –too many have already lost/been denied pain meds.

  2. Considering the emergency severe pain patients are trying to endure, it is disappointing around such efforts as this do not see the need or won’t say ‘Abolish the CDC Guidelines on Opioid Prescribing’.

    No matter when this is scheduled there will be the same fear and resistance and horrifying liability to using Oliceridine as every other previously useful medicinal Opiate.

Leave a Reply to canarensis Cancel reply

%d bloggers like this: